These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 15303778)
1. Imiquimod: a potential weapon against morphea and fibromatoses. Namazi MR J Drugs Dermatol; 2004; 3(4):362-3. PubMed ID: 15303778 [No Abstract] [Full Text] [Related]
2. Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline, open-label pilot study. Pope E; Doria AS; Theriault M; Mohanta A; Laxer RM Dermatology; 2011; 223(4):363-9. PubMed ID: 22327486 [TBL] [Abstract][Full Text] [Related]
3. Localized morphea treated with imiquimod 5% and dermoscopic assessment of effectiveness. Campione E; Paternò EJ; Diluvio L; Orlandi A; Bianchi L; Chimenti S J Dermatolog Treat; 2009; 20(1):10-3. PubMed ID: 18651299 [TBL] [Abstract][Full Text] [Related]
4. Imiquimod. Wooten JM South Med J; 2005 Sep; 98(9):852. PubMed ID: 16217974 [No Abstract] [Full Text] [Related]
5. [Imiquimod and resiquimod. The onset of a new pharmaco-therapeutic class?]. Chosidow O; Cribier B; Aractingi S Ann Dermatol Venereol; 2003; 130(8-9 Pt 1):713-7. PubMed ID: 14576599 [No Abstract] [Full Text] [Related]
7. Effectiveness of imiquimod on Molluscum contagiosum viral chemokines. Campione E; Peris K; Paternò EJ; Chimenti S J Cutan Med Surg; 2007; 11(4):156-8. PubMed ID: 17601424 [No Abstract] [Full Text] [Related]
8. Imiquimod: mode of action and therapeutic potential. Chosidow O; Dummer R Acta Derm Venereol Suppl (Stockh); 2003 Sep; (214):8-11. PubMed ID: 14606276 [No Abstract] [Full Text] [Related]
9. Current and potential uses of imiquimod. Chang YC; Madkan V; Cook-Norris R; Sra K; Tyring S South Med J; 2005 Sep; 98(9):914-20. PubMed ID: 16217984 [TBL] [Abstract][Full Text] [Related]
11. [Pharma clinics. Medication of the month. Imiquimod (Aldara): an immunomodulator for the skin]. Hermanns-Lê T; Nikkels AF; Uhoda I; Petit L; Piérard GE Rev Med Liege; 2002 Feb; 57(2):116-8. PubMed ID: 11942177 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy and safety of topical imiquimod 5% for plaque-type morphea: a multicenter, prospective, vehicle-controlled trial. Dytoc M; Wat H; Cheung-Lee M; Sawyer D; Ackerman T; Fiorillo L J Cutan Med Surg; 2015; 19(2):132-9. PubMed ID: 25775634 [TBL] [Abstract][Full Text] [Related]
13. Use of imiquimod cream 5% in the treatment of localized morphea. Man J; Dytoc MT J Cutan Med Surg; 2004; 8(3):166-9. PubMed ID: 15129316 [TBL] [Abstract][Full Text] [Related]
15. Extensive and refractory genital herpes in human immunodeficiency virus-infected patient successfully treated with imiquimod: Case report and literature review. Camasmie HR; Barbosa C; Lupi O; Lima RB; Serra M; D'Acri AM; Martins CJ Indian J Dermatol Venereol Leprol; 2017; 83(2):256-259. PubMed ID: 28164895 [No Abstract] [Full Text] [Related]
16. New insights into imiquimod's mechanisms of action. Martín-García RF J Drugs Dermatol; 2004; 3(3):247-9. PubMed ID: 15176157 [TBL] [Abstract][Full Text] [Related]
17. Imiquimod and genital herpes. Slade HB; Schacker T; Conant M; Thoming C Arch Dermatol; 2002 Apr; 138(4):534; author reply 534-5. PubMed ID: 11939822 [No Abstract] [Full Text] [Related]
18. Imiquimod: a review of off-label clinical applications. David CV; Nguyen H; Goldenberg G J Drugs Dermatol; 2011 Nov; 10(11):1300-6. PubMed ID: 22052312 [TBL] [Abstract][Full Text] [Related]
19. Genital warts reduced with imiquimod. AIDS Patient Care STDS; 1998 May; 12(5):409. PubMed ID: 11361984 [No Abstract] [Full Text] [Related]